Table 2 Previous regimens at time of switch and main reasons for switch among the 596 cART-experienced patients initiating a RPV/TDF/FTC co-formulation
From: Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
N (%) | |
|---|---|
ART regimen at switch | |
2 NRTIs + EFV | 192 (32.2) |
2 NRTIs + NVP or ETV | 93 (15.6) |
2 NRTIs +1 PI | 156 (26.2) |
2 NRTIs +1 INSTI | 58 (9.7) |
Triple nuke regimen | 44 (7.4) |
Other | 29 (4.9) |
Unknown | 24 (4.0) |
Main reasons for switch | |
Simplification | 266 (44.6) |
CNS toxicity | 143 (24.0) |
Physician decision | 46 (7.7) |
Gatrointestinal/liver toxicity | 42 (7.0) |
Abnormal fat distribution/dyslipidemia/concern of cardiovascular disease | 38 (6.4) |
Other toxicities (including endocrine, haematological, kidney, muscle, skin) | 26(4.4) |
Patient wish/decision | 20 (3.4) |
Drug interaction | 6 (1.0) |
Treatment failure | 1 (0.2) |
Unknown | 8 (1.3) |